|
CN101636179B
(zh)
|
2006-11-07 |
2012-10-10 |
默沙东公司 |
Pcsk9拮抗剂
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
HUE028589T2
(en)
*
|
2008-07-10 |
2016-12-28 |
Toray Industries |
Pharmaceutical preparation for the treatment and prevention of cancer
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
EP3358008A1
(en)
|
2009-09-03 |
2018-08-08 |
Pfizer Vaccines LLC |
Pcsk9 vaccine
|
|
US8877900B2
(en)
|
2009-10-30 |
2014-11-04 |
Merck Sharp & Dohme Corp. |
AX132 PCSK9 antagonists
|
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
EA022983B1
(ru)
*
|
2010-04-13 |
2016-04-29 |
Бристол-Майерс Сквибб Компани |
Белки на основе структурного домена фибронектина, связывающие pcsk9
|
|
US8481688B2
(en)
|
2010-05-11 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies
|
|
GB2481373A
(en)
*
|
2010-06-21 |
2011-12-28 |
Weiming Xu |
Treatment of hypercholesterolaemia by ubiquitination of PCSK9
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
EA201390929A1
(ru)
*
|
2010-12-22 |
2013-12-30 |
Дженентек, Инк. |
Антитела к pcsk9 и способы их применения
|
|
MX366458B
(es)
*
|
2011-01-28 |
2019-07-10 |
Sanofi Biotechnology |
Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
|
|
HK1202804A1
(en)
*
|
2011-07-14 |
2015-10-09 |
辉瑞公司 |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
MX363642B
(es)
*
|
2011-09-16 |
2019-03-28 |
Regeneron Pharma |
Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
|
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
|
US9879093B2
(en)
|
2011-12-20 |
2018-01-30 |
Adaerata, Limited Partnershp |
Single domain antibodies as inhibitors of PCSK9
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
CN104302170B
(zh)
|
2012-03-16 |
2016-09-28 |
瑞泽恩制药公司 |
生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
|
|
NZ730271A
(en)
|
2012-03-16 |
2022-09-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
ES2665793T3
(es)
|
2012-03-16 |
2018-04-27 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
WO2014028354A1
(en)
|
2012-08-13 |
2014-02-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
DK3081249T3
(da)
|
2012-11-21 |
2021-03-15 |
Amgen Inc |
Lægemiddeladministrationsanordning
|
|
SG11201507417RA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Body contour adaptable autoinjector device
|
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
EP3593839A1
(en)
|
2013-03-15 |
2020-01-15 |
Amgen Inc. |
Drug cassette
|
|
EP2970501A2
(en)
*
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
CN113559363B
(zh)
|
2013-03-22 |
2023-10-31 |
美国安进公司 |
注射器及装配方法
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
CN105705521A
(zh)
|
2013-06-07 |
2016-06-22 |
再生元制药公司 |
通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
|
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
|
WO2015051159A1
(en)
*
|
2013-10-02 |
2015-04-09 |
The Rockefeller University |
Amyloid protofibril antibodies and methods of use thereof
|
|
BR112016008946B1
(pt)
|
2013-10-24 |
2022-12-27 |
Amgen Inc |
Injetores e método para montar os injetor
|
|
CA3168888A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
MX2016006226A
(es)
|
2013-11-12 |
2016-09-07 |
Sanofi Biotechnology |
Regimenes de dosificacion para uso con inhibidores de pcsk9.
|
|
US20170173128A1
(en)
*
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
BR112016025852B1
(pt)
|
2014-05-07 |
2022-11-01 |
Amgen Inc |
Dispositivo de injeção para aplicação de fármaco
|
|
SG11201609966SA
(en)
|
2014-06-03 |
2016-12-29 |
Amgen Inc |
Drug delivery system and method of use
|
|
EP3332790A1
(en)
|
2014-07-15 |
2018-06-13 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
DE202015009006U1
(de)
|
2014-07-15 |
2016-08-19 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
RU2735521C2
(ru)
|
2014-07-16 |
2020-11-03 |
Санофи Байотекнолоджи |
Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
EP3193928A1
(en)
|
2014-08-06 |
2017-07-26 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
JP2017533695A
(ja)
|
2014-09-16 |
2017-11-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗グルカゴン抗体およびその使用
|
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
US10695506B2
(en)
|
2014-10-14 |
2020-06-30 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
|
EP3209332B1
(en)
|
2014-10-23 |
2021-05-26 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
MA41022A
(fr)
*
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
EP3233159B1
(en)
|
2014-12-19 |
2020-03-04 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
CN105461809B
(zh)
*
|
2015-02-11 |
2018-10-12 |
康融东方（广东）医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
|
ES2748750T3
(es)
|
2015-02-17 |
2020-03-17 |
Amgen Inc |
Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
|
|
EP3261690B1
(en)
|
2015-02-27 |
2021-12-15 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
|
KR20170123345A
(ko)
|
2015-03-20 |
2017-11-07 |
오르후스 우니베르시테트 |
지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
|
|
CN105037554B
(zh)
*
|
2015-06-12 |
2019-04-12 |
成都贝爱特生物科技有限公司 |
抗人pcsk9抗体的制备及其用途
|
|
EA201890519A1
(ru)
|
2015-08-18 |
2018-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
|
CN106810609A
(zh)
*
|
2015-11-27 |
2017-06-09 |
苏州君盟生物医药科技有限公司 |
抗pcsk9抗体及其应用
|
|
EP3386573B1
(en)
|
2015-12-09 |
2019-10-02 |
Amgen Inc. |
Auto-injector with signaling cap
|
|
WO2017114230A1
(zh)
*
|
2015-12-31 |
2017-07-06 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
CN107531795B
(zh)
*
|
2016-01-05 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
AU2017207862B2
(en)
|
2016-01-13 |
2020-12-17 |
Novo Nordisk A/S |
EGF(A) analogues with fatty acid substituents
|
|
EP4035711B1
(en)
|
2016-03-15 |
2025-06-04 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
|
CN107266575B
(zh)
*
|
2016-04-07 |
2021-12-24 |
天士力生物医药股份有限公司 |
前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
ES2959783T3
(es)
|
2016-05-13 |
2024-02-28 |
Amgen Inc |
Conjunto de cubierta protectora de vial
|
|
US11238150B2
(en)
|
2016-05-16 |
2022-02-01 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
EP3464349A4
(en)
*
|
2016-05-23 |
2020-08-26 |
New York University |
COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
|
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
CN107474140B
(zh)
*
|
2016-06-08 |
2022-06-03 |
常州博嘉生物医药科技有限公司 |
Pcsk9特异性的结合蛋白mv072及其应用
|
|
CA3026474A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
BR112018076242A2
(pt)
*
|
2016-06-24 |
2019-03-26 |
Hoffmann La Roche |
inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
JP7046381B2
(ja)
|
2016-09-20 |
2022-04-04 |
オーフス ウニベルシテット |
リポタンパク質代謝障害の治療のための化合物
|
|
JP2020502991A
(ja)
*
|
2016-09-20 |
2020-01-30 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｐｃｓｋ９抗体
|
|
EP3515949A4
(en)
*
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
NEW ANTI-PCSK9 ANTIBODIES
|
|
WO2018067987A1
(en)
|
2016-10-06 |
2018-04-12 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
US20190248888A1
(en)
|
2016-10-20 |
2019-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
EP3532127A1
(en)
|
2016-10-25 |
2019-09-04 |
Amgen Inc. |
On-body injector
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
CN108239150A
(zh)
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
|
MX2019008432A
(es)
|
2017-01-17 |
2019-11-18 |
Amgen Inc |
Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
|
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
|
MX2019009755A
(es)
|
2017-02-17 |
2019-10-07 |
Amgen Inc |
Mecanismo de insercion para dispositivo de suministro de farmacos.
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
JP2020508803A
(ja)
|
2017-03-06 |
2020-03-26 |
アムジエン・インコーポレーテツド |
作動防止特徴部を備える薬物送達デバイス
|
|
CA3052482A1
(en)
|
2017-03-07 |
2018-09-13 |
Amgen Inc. |
Needle insertion by overpressure
|
|
EP3592404A1
(en)
|
2017-03-09 |
2020-01-15 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
PL3600491T3
(pl)
|
2017-03-28 |
2024-03-04 |
Amgen Inc. |
Układ i sposób montażu trzonu tłoka i strzykawki
|
|
AU2018258676B2
(en)
|
2017-04-28 |
2024-09-19 |
Amgen Inc. |
N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
|
|
EP3634539A1
(en)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
AU2018282077B2
(en)
|
2017-06-08 |
2023-11-23 |
Amgen Inc. |
Torque driven drug delivery device
|
|
WO2018236619A1
(en)
|
2017-06-22 |
2018-12-27 |
Amgen Inc. |
Device activation impact/shock reduction
|
|
MX2019015479A
(es)
|
2017-06-23 |
2020-02-20 |
Amgen Inc |
Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
IL270784B2
(en)
|
2017-07-14 |
2023-11-01 |
Amgen Inc |
Needle insertion-extraction system with a double torsion spring system
|
|
WO2019016306A1
(en)
|
2017-07-19 |
2019-01-24 |
Novo Nordisk A/S |
BIFUNCTIONAL COMPOUNDS
|
|
WO2019018538A1
(en)
*
|
2017-07-20 |
2019-01-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
RECOMBINANT ANTIBODIES BINDING TO CD123
|
|
EP3655063A1
(en)
|
2017-07-21 |
2020-05-27 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
|
JP7242562B2
(ja)
|
2017-07-25 |
2023-03-20 |
アムジエン・インコーポレーテツド |
容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
|
|
EP4085942A1
(en)
|
2017-07-25 |
2022-11-09 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
|
US12025618B2
(en)
|
2017-08-01 |
2024-07-02 |
Amgen Inc. |
Systems and methods for performing a real-time glycan assay of a sample
|
|
JP7237022B2
(ja)
|
2017-08-01 |
2023-03-10 |
アムジエン・インコーポレーテツド |
質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法
|
|
EP3664863A2
(en)
|
2017-08-09 |
2020-06-17 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
|
WO2019036181A1
(en)
|
2017-08-18 |
2019-02-21 |
Amgen Inc. |
BODY INJECTOR WITH STERILE ADHESIVE PATCH
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
US11759565B2
(en)
|
2017-10-04 |
2023-09-19 |
Amgen Inc. |
Flow adapter for drug delivery device
|
|
IL272636B2
(en)
|
2017-10-06 |
2024-10-01 |
Amgen Inc |
Drug delivery device with interlock assembly and related method of assembly
|
|
IL273323B2
(en)
|
2017-10-09 |
2024-10-01 |
Amgen Inc |
Drug delivery device with drive assembly and related assembly method
|
|
IL273582B2
(en)
|
2017-11-03 |
2024-12-01 |
Amgen Inc |
Systems and approaches for sterilizing a drug delivery device
|
|
WO2019090303A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
|
MA50553A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Dispositif d'administration de médicament avec détection de positionnement et de débit
|
|
SG11202002966QA
(en)
|
2017-11-10 |
2020-05-28 |
Amgen Inc |
Plungers for drug delivery devices
|
|
MX2020004996A
(es)
|
2017-11-16 |
2020-08-27 |
Amgen Inc |
Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
|
|
EP3710089A1
(en)
|
2017-11-16 |
2020-09-23 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US12110342B2
(en)
*
|
2018-01-31 |
2024-10-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
|
|
WO2019165326A1
(en)
*
|
2018-02-23 |
2019-08-29 |
REMD Biotherapeutics, Inc |
Calcitonin gene-related peptide (cgrp) antagonist antibodies
|
|
EP4321870B1
(en)
|
2018-03-13 |
2025-07-30 |
Amgen Inc. |
Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
|
|
WO2019178280A1
(en)
|
2018-03-13 |
2019-09-19 |
Amgen Inc. |
Sequential digestion of polypeptides for mass spectrometric analysis
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
US12115360B2
(en)
|
2018-07-24 |
2024-10-15 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
MX2021000748A
(es)
|
2018-07-24 |
2021-03-26 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
|
CN112351804A
(zh)
|
2018-07-24 |
2021-02-09 |
安进公司 |
用于施用药物的输送装置
|
|
US12109389B2
(en)
|
2018-07-31 |
2024-10-08 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
CN113166241B
(zh)
|
2018-08-16 |
2025-02-25 |
约翰霍普金斯大学 |
人类znt8抗体
|
|
CA3106452A1
(en)
|
2018-09-24 |
2020-04-02 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
US12042642B2
(en)
|
2018-09-28 |
2024-07-23 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
CA3110529A1
(en)
|
2018-10-02 |
2020-04-09 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
TWI824026B
(zh)
|
2018-10-05 |
2023-12-01 |
美商安進公司 |
具有劑量指示器之藥物遞送裝置
|
|
EA202191038A1
(ru)
|
2018-10-15 |
2021-07-06 |
Эмджен Инк. |
Способ платформенной сборки для устройства доставки лекарственного средства
|
|
IL313960B2
(en)
|
2018-10-15 |
2025-10-01 |
Amgen Inc |
Drug delivery device with a suppression mechanism
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
ES3010833T3
(en)
|
2018-11-01 |
2025-04-04 |
Amgen Inc |
Drug delivery devices with partial drug delivery member retraction
|
|
JP7769544B2
(ja)
|
2018-12-14 |
2025-11-13 |
アムジエン・インコーポレーテツド |
勾配によるタンパク質濃度定量を伴う使用のためのシステム適合性方法
|
|
JP7483731B2
(ja)
|
2019-02-14 |
2024-05-15 |
アムジエン・インコーポレーテツド |
試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
|
|
US12493019B2
(en)
|
2019-02-20 |
2025-12-09 |
Amgen Inc. |
Methods of determining protein stability
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
EP3935396A1
(en)
|
2019-03-04 |
2022-01-12 |
Amgen Inc. |
In vivo reversibility of high molecular weight species
|
|
EP3948242A1
(en)
|
2019-03-27 |
2022-02-09 |
Amgen Inc. |
Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
|
|
CA3137360A1
(en)
|
2019-04-24 |
2020-10-29 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
ES2997211T3
(en)
|
2019-06-05 |
2025-02-14 |
Amgen Inc |
Methods of identifying attributes of therapeutic proteins
|
|
JP7608439B2
(ja)
|
2019-08-23 |
2025-01-06 |
アムジエン・インコーポレーテツド |
構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
CA3166629A1
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
GB2632564B
(en)
*
|
2020-04-09 |
2025-06-18 |
Verve Therapeutics Inc |
Base editing of angptl3 and methods of using same for treatment of disease
|
|
GB202008860D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
KR20210158693A
(ko)
*
|
2020-06-24 |
2021-12-31 |
바이오스트림테크놀러지스(주) |
항 ｐｃｓｋ９ 항체 및 이의 용도
|
|
TW202227470A
(zh)
|
2020-09-18 |
2022-07-16 |
美商安進公司 |
處理樣本用於肽作圖分析之方法
|
|
AU2021376246A1
(en)
|
2020-11-05 |
2023-06-08 |
Amgen Inc. |
Materials and methods for protein processing
|
|
BR112023024278A2
(pt)
|
2021-05-21 |
2024-01-30 |
Amgen Inc |
Método de otimizar uma receita de enchimento para um recipiente de fármacos
|
|
JP2024534047A
(ja)
*
|
2021-08-20 |
2024-09-18 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
膵臓ベータ細胞の特定のバイオマーカーに対する細胞表面抗体
|
|
WO2023070103A1
(en)
|
2021-10-21 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Modulators of proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
CA3237662A1
(en)
|
2021-11-09 |
2023-05-19 |
Amgen Inc. |
Production of therapeutic proteins
|
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
|
WO2024259275A1
(en)
|
2023-06-14 |
2024-12-19 |
Bristol-Myers Squibb Company |
Near real time sialic acid quantitation of glycoproteins
|
|
WO2025101602A1
(en)
|
2023-11-07 |
2025-05-15 |
Amgen Inc. |
Methods of analyzing amino acid content of a therapeutic protein
|
|
WO2025144700A1
(en)
|
2023-12-27 |
2025-07-03 |
Absci Corporation |
Nanobody library screening using bacterial surface display
|
|
WO2025255028A1
(en)
|
2024-06-03 |
2025-12-11 |
Amgen Inc. |
High-throughput liquid chromatography-mass spectrometry-based peptide mapping
|
|
CN118791609B
(zh)
*
|
2024-09-13 |
2024-11-26 |
江苏凯基生物技术股份有限公司 |
一种抗igf-1的单克隆抗体及制备方法及试剂盒及应用
|